Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 36 (GAPDHP36) is a processed pseudogene found in the human genome, derived by retrotransposition of mRNA originating from the functional GAPDH gene[3]. Unlike the active enzyme GAPDH, which is essential for glycolysis and multiple non-metabolic roles, GAPDHP36 does not produce a protein and has no established biological or therapeutic function. GAPDH pseudogenes such as GAPDHP36 are abundant in mammalian genomes, especially in humans and rodents, and reflect the evolutionary history of the GAPDH gene family[3]. The active, functional form is "glyceraldehyde-3-phosphate dehydrogenase" (GAPDH), an essential glycolytic enzyme, but GAPDHP36 is just one of several dozen human pseudogenes for GAPDH[3][1]. This target is not suitable for therapeutic modulation or drug development because it does not encode a viable target molecule[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 36 (GAPDHP36).